1. Home
  2. BNRG vs CDT Comparison

BNRG vs CDT Comparison

Compare BNRG & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brenmiller Energy Ltd

BNRG

Brenmiller Energy Ltd

HOLD

Current Price

$0.53

Market Cap

2.6M

Sector

N/A

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.42

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNRG
CDT
Founded
2012
2019
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.8M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
BNRG
CDT
Price
$0.53
$1.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
916.1K
99.1K
Earning Date
02-27-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$387,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
843.90
N/A
52 Week Low
$0.45
$1.24
52 Week High
$12.40
$876.00

Technical Indicators

Market Signals
Indicator
BNRG
CDT
Relative Strength Index (RSI) 36.77 43.01
Support Level $0.47 $1.30
Resistance Level $0.56 $1.59
Average True Range (ATR) 0.05 0.12
MACD 0.02 0.02
Stochastic Oscillator 51.14 50.00

Price Performance

Historical Comparison
BNRG
CDT

About BNRG Brenmiller Energy Ltd

Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: